Health professionals can consider digital and mobile interventions as a supplement to regular services to support behaviour change in people at risk of developing chronic conditions.
Everything you need to know about the Cancer Drugs Fund (CDF) and the drugs we appraise.
View board meeting minutes and agendas and papers
Formally endorses resources produced by external organisations that support the implementation of NICE guidance and the use of quality standards.
On this page: What changes are we making? Get involved Who else is involved? Timeline Why we're making these changes Improvements we
How we collect and use your personal information, and your rights under data protection legislation
Biographies of the NICE senior management team and minutes of their meetings
Guidance, advice and support for delivering quality, safety and efficiency in the use of medicines
Evidence-based recommendations on reducing the risk of Creutzfeldt–Jakob disease (CJD) transmission from surgical instruments used for interventional procedures
Dame Philippa Russell, Vice-President of Carers UK and Topic Adviser for the NICE guideline on Supporting Adult Carers
Provider name: Elsevier Lot details Lot 1 Electronic Journals, Electronic Books, Databases, Aggregated Evidence Resource Summaries, Point
Jobs at NICE. Includes current vacancies, roles, location and salary information.
Designed for developers of medicinal products and other similarly regulated technologies. Receive advice from NICE, the European Medicines Agency...
Provider name: SAGE Lot details Lot 2 - Print journals, Electronic journals Provider helpdesk Customer account manager:
The Accelerated Access Collaborative is a fast-track route into the NHS for “breakthrough” medicines and technologies
This guideline covers support for adults (aged 18 and over) who provide unpaid care for anyone aged 16 or over with health or social care needs. It aims to improve the lives of carers by helping health and social care practitioners identify people who are caring for someone and give them the right information and support. It covers carers’ assessments, practical, emotional and social support and training, and support for carers providing end of life care.
Evidence-based recommendations on osimertinib (Tagrisso) for untreated locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (NSCLC)
Everything NICE has said on preventing and controlling healthcare-associated infections in an interactive flowchart
Everything NICE has said on supporting adults carers in an interactive flowchart
Everything NICE has said on diagnosing and treating lung cancer in an interactive flowchart
Where you can find more information about how we operate
NICE recommendations on the use of highly specialised technologies are made by an independent advisory committee called the Highly Specialised...
The information below provides a summary of known issues and upcoming changes related to NICE Evidence Services. This information will be updated...
Evidence-based recommendations on Virtual Touch Quantification for diagnosing and monitoring liver fibrosis in chronic Hepatitis B and C
Larotrectinib (also called Vitrakvi and made by Bayer), a new treatment for a range of cancers, can’t be recommended for use in the NHS because at its current price, it doesn’t have the potential to be cost-effective.
Community pharmacy teams have the potential to play a greater role in health promotion and prevention says NICE, in a new draft quality standard.
Another potentially life-extending drug combination for some people with advanced breast cancer will now be available on the Cancer Drugs Fund (CDF) following its approval by NICE in final guidance published today (15 January 2020).
Everything NICE has said on antibiotic prescribing for self-limiting respiratory tract and ear infections in primary care in an interactive flowchart
Everything NICE has said on diagnosing and managing chronic hepatitis B in children, young people and adults in an interactive flowchart
Everything NICE has said on diagnosing and managing community- and hospital-acquired pneumonia in an interactive flowchart
Everything NICE has said on effective antimicrobial medicine use and preventing the spread of resistant microbes in an interactive flowchart
NICE is unable to make a recommendation about the use in the NHS of atezolizumab (Tecentriq) with carboplatin and nab-paclitaxel for untreated advanced NSCLC
We're aiming to increase and extend the use of data in the development and evaluation of our guidance. Data sources could include: electronic health
NICE accreditation decisions
Join our panel to give your expert advice on tools and resources developed to support NICE guidance.
Quick access to reliable information for health and social care professionals. Search HDAS, and other journals and databases.
Evidence-based recommendations on olaparib (Lynparza) for relapsed platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer in adults with a
Evidence-based recommendations on palbociclib (Ibrance) with fulvestrant for hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer
Everything NICE has said on preventing, identifying and managing neutropenic sepsis in children, young people and adults in an interactive flowchart
To help people access the information they need quickly and easily, we're reviewing how we produce and present guidance.